Expansion of Cambrex’s Milan site makes room for APIs

By Maggie Lynch

- Last updated on GMT

(Image: Getty/LewisTsePuiLung)
(Image: Getty/LewisTsePuiLung)

Related tags API Cambrex italy R&D Manufacturing facility Laboratory

Cambrex completes expansion of its R&D laboratory at its Milan site and adds a 12,000-liter reactor to its manufacturing facility during a $3m investment.

The analytical services provider, Cambrex Corporation, completed the expansion of its site in Milan, Italy. The site now holds a new 150m2 ​R&D laboratory.

Cambrex’s expanded R&D laboratory has both chemistry and analytical development capabilities, after the installation of semi-automated glass-line reactors, multiple high and ultra-performance liquid chromatography, and gas chromatography systems.

A spokesperson for Cambrex told us the expansion enables the company to work on new projects at the site and expand its active pharmaceutical ingredients (APIs) portfolio.

“The patents of many important drugs are coming to an end; therefore, the site is working on new generic products. The investments that have been made in R&D at the site over the last two years have increased the capabilities in development, including the installation of containment facilities at a small scale to allow for the development of potent and highly potent APIs,” ​the Cambrex spokesperson said.

The new laboratory also holds a flow chemistry system for continuous manufacturing development, which the spokesperson said will enable researchers to “look at efficient synthetic routes for APIs and intermediates to generic APIs, where appropriate,” ​added the spokesperson.

Cambrex’s generic API portfolio covers drugs across therapeutic areas including analgesics, anesthesia, and central nervous system disorders.

Additionally, the company installed a 12,000-liter reactor to a current good manufacturing practice (cGMP) manufacturing facility at the Milan location.

The installation of the 12,000-liter reactor, among other updates, was part of a $3m (€2.65m) investment by the company to bolster the intermediates and generic APIs efficiency.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more